Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

MADRID, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis (RA). Baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus kinase (JAK) inhibitor being studied for use in the treatment of certain autoimmune conditions, including RA. Among patients completing the open-label extension, clinical improvements observed at week 24 were sustained at the end of 52 weeks. The results were presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, Spain [EULAR abstract OP0047: Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Study].

The long-term extension of the JADA study evaluated the efficacy and safety of baricitinib in 201 patients taking either 4 mg (n=108) or 8 mg (n=93) once daily for up to 52 weeks. Doses could be escalated to 8 mg once daily at 28 or 32 weeks at the investigator's discretion when the patient presented more than six tender and swollen joints.

As previously reported, in the initial 12-week portion of this study, baricitinib was associated with statistically significant improvements in the signs and symptoms of RA disease versus placebo[1] and these responses were maintained or improved during an additional 12 weeks of blinded treatment.[2]

In the long-term extension, the clinical improvements observed at week 24 were sustained through 52 weeks in RA patients. The following chart summarizes selected efficacy results:

<
'/>"/>
SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. ... developing and commercializing therapeutic products for the prevention ... announces receipt of notice on July 18, 2014 ... NYSE-MKT has accepted the CorMedix plan to regain ... As a result, the NYSE-MKT is continuing the ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... in Pharmaceutical Thin Film,Technology -, WARREN, N.J., ... specializing in quick dissolving thin film pharmaceutical products,today ... No. 7,425,292 from the,United States Patent and Trademark ... to issue on September 16, 2008, relates,to the ...
... Calif., Sept. 11 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... fourth quarter and year-end financial results on September,16, 2008., ... discuss its financial results.,Details for the fiscal year-end call ... 16, 2008 -- Time: 10:30 a.m. ET, 9:30 ...
... Deliver Yield Benefits and Value to Farmers, LONDON, ... a significant growth opportunity in continuing to create more ... and,breeding, leading to more than doubling the company,s 2007,s ... biotechnology, will,tell investors. Padgette will deliver his remarks as ...
Cached Biology Technology:MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 2MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process 3Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 2Monsanto Sees Growing Opportunity for Biotech Traits Globally 3Monsanto Sees Growing Opportunity for Biotech Traits Globally 4
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
Breaking Biology News(10 mins):NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2The microbes make the sake brewery 2
... studied interactions between the loggerhead turtle ( Caretta caretta ) ... water surface, mass beachings, and the effects of climate change ... marine species without causing economic losses for fishermen, the scientists ... carried out by night and in areas more than 35 ...
... EAST LANSING, Mich. A team of Michigan State ... created have uncovered the inner workings of a ... develop new medicines or understand how enzymes repair DNA. ... bacterial enzyme that is important in metabolism. Enzymes in ...
... Copenhagen summit to draft a legally binding agreement on the ... that we will see further rapid changes in the global ... the planet,s most vulnerable species at this time of unprecedented ... on 26 February 2010 in the Journal of Experimental ...
Cached Biology News:How can accidental captures of loggerhead turtles be reduced? 2MSU scientists unlock key enzyme using newly created 'cool' method 2Tackling the challenges of survival in a changing world 2Tackling the challenges of survival in a changing world 3